FindTrial
Sign In

Phase 3 study of EPOCH to maintain hemoglobin levels in hemodialysis patients

Phase 3 study of EPOCH to maintain hemoglobin levels in hemodialysis patients

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220011
Enrollment
Unknown
Registered
2005-09-01
Start date
2005-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal anemia

Interventions

investigational material(s) Generic name etc : Epoetin beta INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investi

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.20 years - 80 years of age 2.hemoglobin between 9.0 g/dl to 12.0 g/dl 3.serum ferritin level and over 100 ng/ml or transferrin saturation and over 20%

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026